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Introduction. Gastrinoma should be suspected when the peptic ulcer(s) is postbulbar, multiple, refractory, or recurrent, or
ulcer is associated with nephrolithiasis, hypocalcaemia, or erosive esophagitis. The majority of gastrinomas are malignant. Case
Presentation.Thepatientisa41-year-oldIranianmanwhohasbeeningoodhealthuntil36monthsagowhenduodenalperforation
and two bouts of upper GI bleeding (GIB), each two months apart occurred. He also mentioned mild watery diarrhoea and
decreased appetite. Serum gastrin level was elevated. Abdominal CT scan revealed pancreatic mass and three enhancing hepatic
masses. CT-guided pancreatic biopsy revealed monotonous cells. Chemoembolization of hepatic metastases was done. New ct
images6monthslatershowednearlytotalregressedhepaticandpancreaticlesions.Conclusion.Besidepreviouslydeﬁnedsituations
that take gastrinoma into account as the etiology of PUD, accumulation of PUD complications is highly suggestive of Zollinger-
Ellisone syndrome (ZES). Regression of pancreatic primary after chemoembolization of hepatic metastases is unexplainable at the
present time.
1.Introduction
Peptic ulcer disease (PUD), specially duodenal ulcer, is a
chronic disease if it’s two main causes, Helicobacter pylori
infection (H. pylori) and nonsteroidal anti-inﬂammatory
drugs use, have not been addressed.
Gastrointestinal bleeding (GIB), perforation, and gastric
outlet obstruction are the complications of PUD.
Upper gastrointestinal (UGI) bleeding secondary to
peptic ulcer is a common medical condition that results in
high patient morbidity, although it appears to be becoming a
less common cause of UGI bleeding.
Nowadays with more and more improvement of sanita-
tionandH.pylori eradication the rate ofidiopathic ulcersare
increasing. Perforation, another complication of duodenal
ulcer, involves the anterior wall of the duodenal bulb in
most cases. Perforated gastric ulcers usually involve the
lesser curvature [1, 2]. Hypergastrinemia and its pancreatic
variant, Zollinger-Ellisone syndrome (ZES), should be borne
in mind in the presence of complications, especially if
nonsteroidal anti-inﬂammatory drugs and H. pylori are not
the causes or diarrhea is also present [3]. Diarrhea is the
only symptom in ten percent of patients [4] and appears
to be less frequent in ZES patients with MEN I syndrome
than in sporadic ZES [5]. After insulinoma, gastrinoma
is the commonest islet cell tumor [6]. However, unlike
insulinomas, the majority of gastrinomas are malignant.
An equal number of gastrinomas occur in the pancreas
and duodenum. The majority of duodenal gastrinomas are
small (<2cm in size), but the majority of the pancreatic
and peripancreatic tumors are greater than two cm in size.
The larger the gastrinoma is, the more likely there will be
metachronous liver metastases [7]. Gastrinomas metastasize
to the liver, lymph nodes, and bone and rarely elsewhere,2 Case Reports in Medicine
Table 1: Laboratory characteristics of the patient.
patient Normal range
Serum gastrin 300pg/mL up to 105pg/mL
Serum calcium 8.8mg/dL 8.5–10.5mg/dL
Serum phosphorus 3.4mg/dL 3–5mg/dL
Serum alkaline phosphatase 191u/L Up to 270u/L
Serum parathyroid hormone 40pg/mL 10–65pg/mL
such as to the heart [8]. MEN I syndrome, an autosomal
dominant disease which beside pancreas (gastrinoma, or
other islet cell tumors) involves parathyroid and pituitary
glands is present in nearly one third of ZES patients [9].
There is a slight male preponderance with a mean age
of 41 years and a mean delay in diagnosis of ﬁve years.
Beside initial correction of hypersecretion state with potent
proton pump inhibitors (PPI), surgery for cure intention
in nonmetastatic sporadic disease is the optimal choice. In
the hands of an experienced surgeon, up to 50 percent of
these patients will be cured [10]. Vagotomy may also be done
in the same session and is specially beneﬁcial in uncured
patients [11]. The purpose of the case presentation is to
introduce a ZES patient with an unusual metachronous
occurrenceoftwotypesofpepticulcercomplicationandalso
his unexpected regression of primary pancreatic mass after
chemoembolization of hepatic metastases.
2. Case Presentation
The patient is a 41-year-old Iranian man who has been in
good health except mild diarrhea until 36 months ago, when
he was suddenly aﬄicted with severe generalized abdominal
pain and rebound in abdominal physical examination. He
was attended by surgeon and was operated on. Surgical
diagnosis was perforated duodenal ulcer. After discharge,
he was prescribed omeprazole for four weeks without any
investigation for H. pylori infection. He hasnot had any past
medical or drug history before operation but he mentioned
mild watery diarrhea and decreased appetite without weight
loss since a few months ago. One month after termination
of omeprazole course, acute upper GI bleeding as melena
occurred and he was again admitted in another hospital.
Endoscopy was done. A small bulbar ulcer was the cause.
Rapid urease test (RUT) was positive. Triple anti-H. pylori
therapy was completed, and omeprazole was continued for
another one month. Twenty days after termination of second
course of omeprazole therapy urease breath test was done
which was negative for active H. pylori infection. No further
medication was administered. Approximately ten days later,
another bout of upper GI bleeding in the form of melena
occurred. He was admitted again in the hospital. Endoscopy
revealed duodenal ulcer. RUT was negative. Regarding the
history and unusual accumulation of peptic ulcer compli-
cations in spite of usual management, hypersecretory states
such as gastrinoma were suspected. The result of serologic
tests at that time is shown in Table 1.
Abdominal computed tomography (CT) scan revealed
a1 0 ×8mm lesion in head of pancreas with peripheral
enhancement (in favor of an islet cell tumor) and three
superﬁcially located enhancing lesions in both hepatic lobes,
in favor of hypervascular metastasis (Figure 1). CT-guided
biopsy of pancreatic lesion was done. Pathologic result was
as follows: section reveals fragments of tissue including
pancreas with a benign neoplasm composed of monotonous
cells looking like gland islets with preservation of the regular
cords. No any nuclear atypia was seen (compatible with
gastrinoma) (Figure 2). Angiography and chemoemboliza-
tion of hepatic metastatic lesions were done using gel
foam, Lipidial, Mitomycin, and Adriablastin. A short while
after the procedure, the patient felt severe abdominal pain,
that was managed symptomatically with opioid analgesics,
and omeprazole 20mg daily was continued. Now, after 36
months, the patient is in good health and receives omepra-
zole 20mg daily. NewCT images showed aquestionable faint
enhanced lesion which shows decreased size and diminished
enhancement compared to pre-embolization study. The
pancreatic head is prominent without any apparent mass
lesion (Figure 3).
3. Discussion
Peptic ulcers are used to recuring in similar manner as
previous presentations. Metachronous occurrence of two
types of complication in a single patient is extremely rare.
Persistent H. pylori infection, the use of nonsteroidal anti-
inﬂammatorydrugs,smoking,andacidhypersecretorystates
are the causes of ulcer recurrence. Gastrinoma speciﬁcally
should be suspected if ulcers are postbulbar, multiple,
refractory, or recurrent despite H. pylori eradication or
ulcer is associated with nephrolithiasis, hypercalcemia, or
erosive esophagitis or strong positive family history of
PUD. Relative to older studies in which multiple ulcers,
peptic ulcer complications, and ulcer in atypical locations
were frequent, most patients today with ZES have typical
duodenal ulcer and up to 29% have no ulcer at diagnosis
[12]. In the given patient, decreased appetite, diarrhea,
recurrent duodenal ulcer despite H. pylori eradication, and
the presence of two metachronous PUD complications
support the clinical suspicion of ZES. In highly selected
patients in whom the perforation seems to have sealed,
non operative therapy may be appropriate [13]. In some
rare cases, hypergastrinemia due to gastrinoma may be the
cause of recurrence or ulcer nonhealing. The liver is the
major metastatic site for gastrinomas, as it is with other
islet cell tumors. The second most common site is bone (7
percent of patients in one series), almost all of which occur
in patients who also have liver metastases [14]. Somato-
statin analogs such as octreotide specially in octreoscan
positive metastatic tumors can reduce gastrin levels and
may slow tumor growth [15]. Hepatic resection may be
considered for the treatment of metastatic liver disease in
the absence of diﬀuse bilobar involvement, compromised
liver function, or extensive extrahepatic metastases (e.g.,
pulmonary, peritoneal). Although the majority of cases will
not be cured by surgery, prolonged survival is often possible,
given the slow-growing nature of these tumors. Hepatic
arterial embolization with or without selective hepatic arteryCase Reports in Medicine 3
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Figure 1: Pancreatic head mass lesion with peripheral enhancement (in favour of an islet cell tumor) and three enhancing lesions in both
hepatic lobes, in favour of hypervascular metastasis.
(a) (b)
Figure 2: Monotonous cells look like gland islets with preservation of the regular cords, compatible with gastrinoma.
infusion of chemotherapy is frequently applied as a palliative
technique in patients with symptomatic hepatic metastases
who are not candidates for surgical resection. The response
rates associated with embolization or chemoembolization,
as measured either by decrease in hormonal secretion or
by radiographic regression, are generally greater than 50
percent [16]. However, the duration of response can be brief,
ranging from 4 to 24 months in uncontrolled series [17, 18].
In one of the largest reports of 81 patients undergoing
embolization or chemoembolization for carcinoid tumor,
the median duration of response was 17 months, and the
probability of progression-free survival (PFS) at one, two,
and three years was 75, 35, and 11 percent, respectively
[17]. A second series of 69 patients with carcinoid and
54 with pancreatic islet cell tumors suggested better results
for carcinoid (response rate 67 versus 35 percent, median
PFS 23 versus 16 months, and median overall survival 34
versus 23 months) [18]. The addition of chemotherapy
to hepatic artery embolization seemed to beneﬁt islet cell
tumors but not carcinoids. Early studies noted a signif-
icant incidence of severe postembolization complications,
including renal failure, hepatic necrosis, and sepsis. More
recently, improvements in technique have reduced the
incidence of such complications, making embolization an
important and generally safe treatment option for patients
with metastatic NETs [17]. Nevertheless, careful patient4 Case Reports in Medicine
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Figure 3: Regression of hepatic lesions 18 months after chemoembolization.
selection is mandatory because of treatment and disease-
relatedadverseeﬀects,whichcanrangefromtransientsymp-
toms (pain, nausea, fever, fatigue) as occurred in our patient,
biochemical abnormalities (elevated liver enzymes) to ﬂorid
carcinoid crisis which may be fatal. Regression of pancreatic
primarymassafterchemoembolizationofhepaticmetastases
was a unique and unexpected event. At the present time,
there is not a documented explanation. However, a variant
vascular communication between tributaries of hepatic and
pancreaticoduodenal arteries or unusual high sensitivity of
pancreatic tumoral lesion to chemotherapeutic agents leaked
to systemic circulation may be the case [19]. Radiofrequency
ablation, cryoablation, and liver transplantation may also
be beneﬁcial as liver-directed therapies. Experience with
Chemotherapy and targeted radiotherapy for metastatic gas-
trinoma is limited [20]. In an illustrative series, 185 patients
with ZES were followed prospectively for a mean of 12.5
years [21]. The following results were noted: liver metastases
were found in 24 percent of patients at the time of diagnosis;
the majority of these patients had a primary pancreatic
neoplasm, and 67 percent had primary tumours that were
greater than 3cm in size. Patients with liver metastases had
a 10-year survival of only 30 percent compared to a 15-
year survival of 83 percent in those without liver metastases.
Patients with lymph node metastases had the same mortality
as those who were free of visceral metastases. Patients with
MEN 1 had a signiﬁcantly lower rate of metastasis at the time
ofinitialdiagnosis(6percent);theirhighoverallsurvivalrate
(100 percent at 20 years) reﬂected this fact.
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